Dietary intervention primes triple-negative breast cancer for targeted therapy

July 14, 2015, University of Wisconsin-Madison

A diet that starves triple-negative breast cancer cells of an essential nutrient primes the cancer cells to be more easily killed by a targeted antibody treatment, UW Carbone Cancer Center scientists report in a recent publication.

The study's senior author, Vincent Cryns, professor of medicine at the University of Wisconsin School of Medicine and Public Health, says the study lays the foundation for a clinical trial to see if a low-methionine diet will help improve outcomes in women with "triple-negative" .

Methionine is an essential amino acid that is present in low concentrations in some vegan diets.

Patients with have limited treatment options because their lack the three receptors—estrogen, progesterone and human epidermal growth factor receptor 2 (HER-2)—commonly targeted in hormone or chemotherapy.

The journal Clinical Cancer Research chose the paper as a highlighted study in its June 15 edition.

Scientists have known for decades that methionine deficiency can block the growth of many types of cancer, but the underlying mechanisms have puzzled researchers.

"We've shown that removing methionine can have a specific effect on a molecular pathway that regulates cell death to increase the vulnerability of cancer cells to treatments that target this pathway," Cryns says. "What's particularly exciting about our findings is that they suggest that a dietary intervention can increase the effectiveness of a targeted cancer therapy."

Specifically, the researchers showed that when triple-negative breast cancer cells were deprived of methionine—an essential nutrient abundant in meat, fish, some legumes and nuts, but low in fruits and vegetables—the stressed cancer cells responded by increasing the amount of a receptor on the cell's surface called TRAIL-R2.

This resulted in the becoming very sensitive to an antibody that binds to TRAIL-R2 on the surface of the cancer cells and triggers them to die.

"What we didn't anticipate is that the normal, non-cancer cells didn't upregulate the receptor under methionine stress the way the tumor cells did," Cryns says. "This shows that diet can help expose a targetable defect in ."

Lead author Elena Strekalova, a scientist in the Cryns lab, and the research team fed mice with triple-negative breast tumors a diet lacking methionine and treated them with an antibody that binds to the TRAIL-R2 receptor. Mice, like humans, can tolerate a methionine-free diet for a short period of time. The combination of diet and antibody was more effective at shrinking the breast tumors and preventing metastasis to the lungs than either treatment alone.

The University of Wisconsin team believes that their laboratory studies may pave the way for a clinical trial in to examine the effectiveness of a low-methionine diet in combination with a TRAIL-R2 monoclonal antibody. When used alone, TRAIL-R2 antibodies have not been effective in patients with metastatic solid tumors.

Cryns hopes that brief exposure to a low methionine diet will boost the effectiveness of TRAIL-R2 antibodies in patients, as it did in mice. "We still have much to learn," Cryns indicates, "but we believe that uncovering the molecular effects of specific nutritional interventions like a low methionine will open up new treatment options for cancer."

Explore further: Even low-androgen triple-negative breast cancer responds to anti-androgen therapy

Related Stories

Even low-androgen triple-negative breast cancer responds to anti-androgen therapy

February 24, 2015
A University of Colorado Cancer Center study published today in the journal Molecular Cancer Therapeutics shows that only about 1 percent of triple-negative breast cancer cells in a tumor must be "androgen-receptor-positive" ...

Scientists link protein with breast cancer's spread to the brain

January 6, 2014
A cancer-research team at the University of Wisconsin-Madison has identified a protein that may be a major culprit when breast cancer metastasizes to the brain.

Molecular signature for outcomes of triple negative breast cancer

April 13, 2015
Compared to other types of breast cancer, triple negative breast cancers are often more aggressive and have fewer treatment options. In a new study published in the journal Proceedings of the National Academy of Sciences ...

Immune therapy tested in study of women with triple-negative breast cancer

April 20, 2015
Early data in a preliminary human study show that an experimental immune system drug is generally safe and well tolerated in women with metastatic, triple-negative breast cancer, a persistently difficult form of the disease ...

Diet rich in methionine may promote memory loss

March 31, 2015
Memory loss has recently been associated with excessive silencing of genes through a process called methylation. Researchers at the University of Louisville investigated the effects of a diet rich in methionine—an amino ...

Virus kills triple negative breast cancer cells, tumor cells in mice

June 24, 2014
A virus not known to cause disease kills triple-negative breast cancer cells and killed tumors grown from these cells in mice, according to Penn State College of Medicine researchers. Understanding how the virus kills cancer ...

Recommended for you

Metastatic cancer gorges on fructose in the liver

April 26, 2018
Biomedical engineers at Duke University have demonstrated that metastatic cancer cells can reprogram their metabolism to thrive in new organs. Specifically, the research shows that cells originating from colorectal cancer ...

Breast cancer genes a real risk for men, too

April 26, 2018
(HealthDay)—Few American men are screened for gene mutations that can greatly increase their risk of breast and other types of cancers, a new study reveals.

Largest-ever study of thyroid cancer genetics finds new mutations, suggests immunotherapy

April 26, 2018
University of Colorado Cancer Center researchers recently completed the largest-ever study of thyroid cancer genetics, mining the data of 583 patient samples of advanced differentiated thyroid cancer and 196 anaplastic thyroid ...

Molecular culprit behind virus-mediated chronic inflammation and cancers identified

April 26, 2018
Within cells infected by Kaposi sarcoma herpesvirus (KSHV), the human protein CADM1 interacts with viral proteins to promote chronic inflammation, which plays a major role in the development of cancers caused by KSHV. Richard ...

PARP-1 may be key to effectiveness of PARP inhibitors, and now researchers can image it

April 26, 2018
Penn Medicine researchers have used CRISPR/Cas9 gene editing technology to isolate a key genetic feature that could cause resistance to PARP inhibitors in patients with ovarian cancer—and they've also proven they have a ...

Blood cancer precursor found in 9/11 firefighters

April 26, 2018
A study in today's issue of JAMA Oncology reports that New York City firefighters exposed to the 9/11 World Trade Center disaster site face an increased risk for developing myeloma precursor disease (MGUS), which can lead ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.